Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 1.00 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.60 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.60 |
| ▸ | APLNR | P35414 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL770478 | 1.00 | ALDH1A1 (1.00) | ALDH1A1EPHX1HIF1AAPLNRCYP3A4 | |
| SCHEMBL18136465 | 1.00 | ALDH1A1 (1.00) | ALDH1A1EPHX1HIF1AAPLNRCYP3A4 | |
| SCHEMBL2567809 | 1.00 | ALDH1A1 (1.00) | ALDH1A1EPHX1HIF1AAPLNRCYP3A4 | |
| SCHEMBL13174777 | 1.00 | ALDH1A1 (1.00) | ALDH1A1EPHX1HIF1AAPLNRCYP3A4 | |
| SCHEMBL8620 | 1.00 | — | — | |
| SCHEMBL1164134 | 1.00 | ALDH1A1 (1.00) | ALDH1A1EPHX1HIF1AAPLNRCYP3A4 | |
| SCHEMBL12338087 | 1.00 | ALDH1A1 (1.00) | ALDH1A1EPHX1HIF1AAPLNRCYP3A4 | |
| SCHEMBL12513617 | 1.00 | ALDH1A1 (1.00) | ALDH1A1EPHX1HIF1AAPLNRCYP3A4 | |
| SCHEMBL15492354 | 1.00 | ALDH1A1 (1.00) | ALDH1A1EPHX1HIF1AAPLNRCYP3A4 | |
| SCHEMBL16230018 | 1.00 | ALDH1A1 (1.00) | ALDH1A1EPHX1HIF1AAPLNRCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10851080-B2 | Methods of treatment using pyrrolidinyl urea, thiourea, guanidine and cyanoguanidine compounds | ARRAY BIOPHARMA INC. (US) | 2020-12-01 | — | — | US | disclosed |
| US-20180179182-A1 | METHODS OF TREATMENT USING PYRROLIDINYL UREA, THIOUREA, GUANIDINE AND CYANOGUANIDINE COMPOUNDS | ARRAY BIOPHARMA INC. (US) | 2018-06-28 | — | — | US | disclosed |
| US-9828360-B2 | Pyrrolidinyl urea, thiourea, guanidine and cyanoguanidine compounds as TrkA kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2017-11-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180179182-A1 | METHODS OF TREATMENT USING PYRROLIDINYL UREA, THIOUREA, GUANIDINE AND CYANOGUANIDINE COMPOUNDS | RNMT, MTAP, GMPS | ALDH1A1 3489/4885EPHX1 3160/4885HIF1A 742/4885 |
| US-10851080-B2 | Methods of treatment using pyrrolidinyl urea, thiourea, guanidine and cyanoguanidine compounds | RNMT, MTAP, GMPS | ALDH1A1 3489/4885EPHX1 3160/4885HIF1A 742/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.